These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 19190588)

  • 1. Does intensive glycemic control for type 2 diabetes mellitus have long-term benefits for cardiovascular disease risk?
    Soldatos G; Cooper ME
    Nat Clin Pract Endocrinol Metab; 2009 Mar; 5(3):138-9. PubMed ID: 19190588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic memory: Evolving concepts.
    Misra A; Bloomgarden Z
    J Diabetes; 2018 Mar; 10(3):186-187. PubMed ID: 29091343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up after tight control of blood pressure in type 2 diabetes.
    Holman RR; Paul SK; Bethel MA; Neil HA; Matthews DR
    N Engl J Med; 2008 Oct; 359(15):1565-76. PubMed ID: 18784091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
    Dailey G
    Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.
    Vinik A
    Clin Ther; 2007; 29 Spec No():1236-53. PubMed ID: 18046925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
    Ma J; Yang W; Fang N; Zhu W; Wei M
    Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [United Kingdom Prospective Diabetes Study (UKPDS): 10 years later].
    Scheen AJ; Paquot N; Lefebvre PJ
    Rev Med Liege; 2008 Oct; 63(10):624-9. PubMed ID: 19009971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral antidiabetic agents: current role in type 2 diabetes mellitus.
    Krentz AJ; Bailey CJ
    Drugs; 2005; 65(3):385-411. PubMed ID: 15669880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology of Diabetes Interventions and Complications (EDIC). Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort.
    Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group
    Diabetes Care; 1999 Jan; 22(1):99-111. PubMed ID: 10333910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term benefits of early intensive therapy in chronic diseases-the legacy effect.
    Zoccali C; Mallamaci F; Tripepi G; Fu EL; Stel VS; Dekker FW; Jager KJ
    Clin Kidney J; 2023 Nov; 16(11):1917-1924. PubMed ID: 37915902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legacy Effect of Intensive Blood Glucose Control on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Very High Risk or Secondary Prevention of Cardiovascular Disease: A Meta-analysis of Randomized Controlled Trials.
    Zhang X; Liu Y; Zhang F; Li J; Tong N
    Clin Ther; 2018 May; 40(5):776-788.e3. PubMed ID: 29656857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exogenous insulin administration and cardiovascular risk in non-insulin-dependent and insulin-dependent diabetes mellitus.
    Genuth S
    Ann Intern Med; 1996 Jan; 124(1 Pt 2):104-9. PubMed ID: 8554200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association between 7 years of intensive treatment of type 1 diabetes and long-term mortality.
    ; Orchard TJ; Nathan DM; Zinman B; Cleary P; Brillon D; Backlund JY; Lachin JM
    JAMA; 2015 Jan; 313(1):45-53. PubMed ID: 25562265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of Intensive Blood Pressure Treatment in Patients With Type 2 Diabetes Mellitus Receiving Standard but Not Intensive Glycemic Control.
    Tsujimoto T; Kajio H
    Hypertension; 2018 Aug; 72(2):323-330. PubMed ID: 29967045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of self-monitoring of blood glucose (SMBG) for patients with type 2 diabetes and not on insulin: impact of modelling assumptions on recent Canadian findings.
    Tunis SL
    Appl Health Econ Health Policy; 2011 Nov; 9(6):351-65. PubMed ID: 21892840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Legacy effects from DCCT and UKPDS: what they mean and implications for future diabetes trials.
    Murray P; Chune GW; Raghavan VA
    Curr Atheroscler Rep; 2010 Nov; 12(6):432-9. PubMed ID: 20652839
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.